Last reviewed · How we verify
Administration of a PET radiotracer
Administration of a PET radiotracer is a Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development for Diagnosis of various diseases, including cancer, neurological disorders, and cardiovascular conditions.
This PET radiotracer is used to visualize and diagnose various diseases by emitting radiation that can be detected by a PET scanner.
This PET radiotracer is used to visualize and diagnose various diseases by emitting radiation that can be detected by a PET scanner. Used for Diagnosis of various diseases, including cancer, neurological disorders, and cardiovascular conditions.
At a glance
| Generic name | Administration of a PET radiotracer |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Therapeutic area | Nuclear Medicine |
| Phase | Phase 2 |
Mechanism of action
The radiotracer accumulates in specific tissues or organs, allowing for the visualization of their structure and function. This information can be used to diagnose and monitor diseases such as cancer, neurological disorders, and cardiovascular conditions.
Approved indications
- Diagnosis of various diseases, including cancer, neurological disorders, and cardiovascular conditions
Common side effects
- Radiation exposure
Key clinical trials
- Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT (NA)
- 64Cu-GRIP B in Patients With Advanced Malignancies (PHASE1, PHASE2)
- Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases (EARLY_PHASE1)
- DK222 Study at Hopkins (PHASE1)
- Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 (PHASE2)
- Imaging Depression in Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of a PET radiotracer CI brief — competitive landscape report
- Administration of a PET radiotracer updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Administration of a PET radiotracer
What is Administration of a PET radiotracer?
How does Administration of a PET radiotracer work?
What is Administration of a PET radiotracer used for?
Who makes Administration of a PET radiotracer?
What development phase is Administration of a PET radiotracer in?
What are the side effects of Administration of a PET radiotracer?
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline
- Therapeutic area: All drugs in Nuclear Medicine
- Indication: Drugs for Diagnosis of various diseases, including cancer, neurological disorders, and cardiovascular conditions
- Compare: Administration of a PET radiotracer vs similar drugs
- Pricing: Administration of a PET radiotracer cost, discount & access